Literature DB >> 12908723

Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity.

Markus Backmund1, Kirsten Meyer, Martin Wächtler, Dieter Eichenlaub.   

Abstract

BACKGROUND: Hepatitis C Virus (HCV) infection is the most common disease among intravenous drug users (IDUs). PATIENTS AND
METHOD: All patients admitted to the detoxification unit 1991-1997 and meeting ICD-10 diagnosis of opioid dependency were tested for anti-HCV serology.
RESULTS: Thousand and forty nine patients were included in the study. About 61.3% of the IDUs were anti-HCV positive. Increasing age (PR: 1.46; 95% CI: 1.34-1.60), living with a significant other drug user (PR: 1.17; 95% CI: 1.05-1.31), history of therapy (PR: 1.62; 95% CI: 1.50-1.74), history of imprisonment (PR: 1.48; 95% CI: 1.36-1.61), history of emergency treatment (PR: 1.23; 95% CI: 1.12-1.35), additional daily consumption of benzodiazepines (PR: 1.10; 95% CI: 1.00-2.21) or alcohol (PR: 1.26; 95% CI: 1.14-1.38), frequency of injecting heroin (daily: PR: 0.86; 95% CI: 0.78-0.96; previously: PR: 1.14; 95% CI: 1.03-1.26) and type of opioid dependency (methadone: PR: 1.26; 95% CI: 1.13-1.41) were significant factors, considered as individual factors, for positive anti-HCV serology. Using multiple logistic regression we found that older age (OR: 3.54, 95% CI: 1.30-9.67), longer duration of opioid use (OR: 5.74; 95% CI: 1.82-18.13), living with a significant other drug user (OR: 1.47; 95% CI: 1.01-2.16), history of therapy (OR: 4.87; 95% CI: 1.67-14.20), history of imprisonment (OR: 1.92; 95% CI: 1.12-3.28), history of emergency treatment (OR: 1.45; 95% CI: 1.06-1.99) and additional daily consumption of alcohol (OR: 1.49; 95% CI: 1.04-2.13) remained independently associated with positive anti-HCV serology.
CONCLUSIONS: These data support the need for early prevention strategies, namely, education of teachers in schools and further training of counsellors informing IDUs of what they can do to minimise the risk of becoming infected or of transmitting infectious agents to others.

Entities:  

Mesh:

Year:  2003        PMID: 12908723     DOI: 10.1023/a:1024603517136

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  16 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

2.  Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania.

Authors:  Barrot H Lambdin; Jennifer Lorvick; Jessie K Mbwambo; John Rwegasha; Saria Hassan; Paula Lum; Alex H Kral
Journal:  Int J Drug Policy       Date:  2017-06-17

3.  Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.

Authors:  Prem H Thurairajah; Doha Hegazy; Andrew Demaine; Edward R Kaminski; Matthew E Cramp
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

4.  Morphine withdrawal enhances hepatitis C virus replicon expression.

Authors:  Chuan-Qing Wang; Yuan Li; Steven D Douglas; Xu Wang; David S Metzger; Ting Zhang; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

5.  Prevalence of hepatitis C in a German prison for young men in relation to country of birth.

Authors:  M F Meyer; H Wedemeyer; M Monazahian; J Dreesman; M P Manns; M Lehmann
Journal:  Epidemiol Infect       Date:  2006-07-07       Impact factor: 2.451

6.  Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002.

Authors:  Miriam Gerlich; Patrick Gschwend; Ambros Uchtenhagen; Alexander Krämer; Jürgen Rehm
Journal:  Eur J Epidemiol       Date:  2006-07-21       Impact factor: 8.082

7.  Heroin use promotes HCV infection and dysregulates HCV-related circulating microRNAs.

Authors:  Yu Zhou; Li Sun; Xu Wang; Li Zhou; Jieliang Li; Manqing Liu; Fang Wang; Jinsong Peng; Xi'en Gui; Huaqing Zhao; Nancy Reichenbach; Dunjin Zhou; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-09       Impact factor: 4.147

8.  Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users.

Authors:  Li Ye; Xu Wang; David S Metzger; Eric Riedel; Luis J Montaner; Wenzhe Ho
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

9.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais; Corina Lelutiu-Weinberger
Journal:  Am J Epidemiol       Date:  2008-10-09       Impact factor: 4.897

10.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users.

Authors:  Markus Backmund; Kirsten Meyer; Brian R Edlin
Journal:  Clin Infect Dis       Date:  2004-10-26       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.